Neos Therapeutics Inc. (NEOS) Shares Down 4.7%

neos-therapeutics-inc-neos-shares-down-47.png

Neos Therapeutics Inc. (NASDAQ:NEOS)’s share price was down 4.7% during trading on Tuesday . The company traded as low as $7.32 and last traded at $7.44, with a volume of 63,849 shares traded. The stock had previously closed at $7.81.
A number of equities analysts recently commented on NEOS shares. BMO Capital Markets reiterated a “buy” rating and issued a $15.00 target price on shares of Neos Therapeutics in a research report on Tuesday, July 19th. Wells Fargo & Co. reiterated a “buy” rating on shares of Neos Therapeutics in a research report on Wednesday, May 18th. Zacks Investment Research cut shares of Neos Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, May 18th. Finally, Royal Bank Of Canada decreased their target price on shares of Neos Therapeutics from $33.00 to $29.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 17th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Neos Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $21.75.
The stock’s 50-day moving average price is $7.70 and its 200-day moving average price is $9.19. The stock’s market cap is $120.04 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/13/neos-therapeutics-inc-neos-shares-down-4-7.html

Neos Therapeutics (NASDAQ:NEOS) last announced its quarterly earnings results on Thursday, August 11th. The company reported ($1.65) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.16) by $0.49. The business earned $1.49 million during the quarter, compared to analyst estimates of $1.48 million. Neos Therapeutics had a negative net margin of 968.81% and a negative return on equity of 80.10%. On average, equities analysts expect that Neos Therapeutics Inc. will post ($5.38) EPS for the current fiscal year.
In other Neos Therapeutics news, CFO Richard I. Eisenstadt purchased 3,710 shares of the stock in a transaction that occurred on Thursday, August 25th. The stock was purchased at an average cost of $6.82 per share, with a total value of $25,302.20. Following the completion of the acquisition, the chief financial officer now directly owns 3,710 shares of the company’s stock, valued at approximately $25,302.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 4.85% of the stock is owned by corporate insiders.
A number of institutional investors have recently made changes to their positions in the stock. Perceptive Advisors LLC increased its position in shares of Neos Therapeutics by 526.9% in the second quarter. Perceptive Advisors LLC now owns 626,876 shares of the company’s stock worth $4,611,000 after buying an additional 526,876 shares during the period. BlackRock Fund Advisors increased its position in shares of Neos Therapeutics by 58.5% in the second quarter. BlackRock Fund Advisors now owns 566,112 shares of the company’s stock worth $5,254,000 after buying an additional 209,054 shares during the period. Vanguard Group Inc. increased its position in shares of Neos Therapeutics by 12.3% in the second quarter. Vanguard Group Inc. now owns 293,989 shares of the company’s stock worth $2,729,000 after buying an additional 32,266 shares during the period. BlackRock Institutional Trust Company N.A. increased its position in shares of Neos Therapeutics by 52.7% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 172,536 shares of the company’s stock worth $1,601,000 after buying an additional 59,533 shares during the period. Finally, State Street Corp increased its position in shares of Neos Therapeutics by 61.2% in the second quarter. State Street Corp now owns 104,530 shares of the company’s stock worth $972,000 after buying an additional 39,705 shares during the period. 37.73% of the stock is owned by hedge funds and other institutional investors.
About Neos Therapeutics
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Receive News & Ratings for Neos Therapeutics Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Neos Therapeutics Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

Be the first to comment on "Neos Therapeutics Inc. (NEOS) Shares Down 4.7%"

Leave a comment

Your email address will not be published.


*